Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,868 matching trials from the live ClinicalTrials.gov search.
Conditions
Raynaud, Scleroderma
Interventions
Fasudil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Withdrawn No phase listed Observational Accepts healthy volunteers

Clinical Applications of High-Frequency Oscillations

NCT00600717
Conditions
Epilepsy, Migraine, Headache, Pain, Autism, Cerebral Palsy, Brain Development, Traumatic Brain Injury, ADHD - Attention Deficit Disorder With Hyperactivity, Mental Health
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 69 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Diabetes Mellitus, Type 1
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Mateo, California
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Conditions
Lung Cancer
Interventions
cine MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Healthy Volunteer
Interventions
Pirfenidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Merritt Island, Florida
Conditions
Anesthesia
Interventions
Modified Time Principle Induction (MTPI) with rocuronium, RSI succinylcholine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pulmonary Disease, Critical Illness
Interventions
There is no intervention in this observational study
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Completed No phase listed Observational Accepts healthy volunteers Results available

Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children

NCT00894738
Conditions
Mental Disorders
Interventions
Testing (MRS, US, DEXA, blood tests)
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 2 Interventional Results available

Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia

NCT02411578
Conditions
Diabetes Mellitus, Type 1
Interventions
G-Pen Mini™ (glucagon injection), Glucose Tablets
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Completed Not applicable Interventional Accepts healthy volunteers

Perceptions of and Reactions to Sustainability Menu Label Designs

NCT07214792
Conditions
Food Choices
Interventions
Control (QR) Labels, Low Sustainability Labels, Unsustainable Labels, Environmental Harm Labels, High Environmental Harm Labels, High Environmental Cost Labels, Numeric Environmental Cost Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
14,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Heart Diseases, Diabetes, Obesity
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Not applicable Interventional Accepts healthy volunteers

Multinight CPAP for Sleep Apnea Patients

NCT02635100
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
CPAP machine with MNT algorithm
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg, Benicar HCT® Tablets 40 mg/25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Black Pepper on Energy Expenditure and Substrate Utilization

NCT01729143
Conditions
Obesity
Interventions
24-hour energy expenditure and substrate utilization
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Kannapolis, North Carolina
Conditions
Prediabetes
Interventions
Hourly 3-Minute Light Walking Breaks, Hourly Stair-Climbing Exercise Snacks
Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
50 mg Usnoflast, 75 mg Usnoflast, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 12 more
Conditions
Type 2 Diabetes
Interventions
Mitoglitazone, Pioglitazone, Placebo
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

NCT03781115
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine, Placebo Comparator
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Healthy
Interventions
Alprazolam Extended-Release Tablets 3 mg, Xanax XR® Tablets (3 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Healthy
Interventions
Nabumetone 750 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Morrisville, North Carolina
Conditions
Healthy Participants
Interventions
AZD8965, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California